Health Care [ 4/12 ] | Biotechnology [ 18/72 ]
NASDAQ | Common Stock
Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas.
The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs).
Its investigational HAVs are designed to be easily implanted into any patient without inducing a foreign body response or leading to immune rejection.
The company is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; and coronary artery bypass grafting, as well as developing its HAVs for pediatric heart surgery and cellular therapy delivery, including pancreatic islet cell transplantation to treat Type 1 diabetes.
The company was founded in 2004 and is headquartered in Durham, North Carolina.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Jun 11, 24 | -0.29 Increased by +19.44% | -0.22 Decreased by -31.82% |
| Mar 4, 24 | -0.24 Decreased by -500.00% | -0.24 |
| Nov 9, 23 | -0.25 Increased by 0.00% | -0.25 |
| Aug 14, 23 | -0.22 Decreased by -162.86% | -0.22 |
| May 12, 23 | -0.36 Decreased by -89.47% | -0.21 Decreased by -71.43% |
| Mar 24, 23 | -0.04 Decreased by -109.76% | -0.23 Increased by +82.61% |
| Nov 10, 22 | -0.25 Increased by +65.28% | -0.21 Decreased by -19.05% |
| Aug 12, 22 | 0.35 Increased by +146.05% | -0.22 Increased by +259.09% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 0.00 Decreased by N/A% | -26.00 M Decreased by -2.23% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | -22.71 M Decreased by -124.61% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0.00 Decreased by N/A% | -61.84 M Decreased by -275.52% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 0.00 Decreased by N/A% | 13.57 M Decreased by -68.12% | Increased by +N/A% Decreased by N/A% |
| Sep 30, 22 | 0.00 Decreased by N/A% | -25.43 M Increased by +19.44% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 22 | 0.00 Decreased by N/A% | 92.27 M Increased by +636.50% | Increased by +N/A% Decreased by N/A% |
| Mar 31, 22 | 0.00 Decreased by N/A% | -16.47 M Increased by +18.88% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 21 | 0.00 Decreased by N/A% | 42.59 M Increased by +362.68% | Increased by +N/A% - |